Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

E2F1 as a target: promoter-driven suicide and small molecule modulators.

William G Kaelin1

  • 1Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA. william_kaelin@dfci.harvard.edu

Cancer Biology & Therapy
|September 26, 2003
PubMed
Summary

Cancer cells evade growth controls and anti-growth signals due to mutations affecting the retinoblastoma protein (pRB). This impacts E2F transcription factors, driving cell proliferation and potentially apoptosis, offering cancer treatment targets.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

KDM6 Enzymes are the Mechanistic Targets of Mutant IDH that Dictate Replication Stress Sensitivity.

bioRxiv : the preprint server for biology·2026
Same author

Publisher Correction: argeting of HIF2-driven cachexia in kidney cancer.

Nature medicine·2026
Same author

Targeting of HIF2-driven cachexia in kidney cancer.

Nature medicine·2025
Same author

The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs.

Nature communications·2025
Same author

HIF2-driven PTHrP Causes Cachexia and Hypercalcemia in Kidney Cancer: Treatment with HIF2 Inhibitors.

bioRxiv : the preprint server for biology·2025
Same author

Making sense of low-complexity domains: The 2025 Lasker Basic Science Award.

Proceedings of the National Academy of Sciences of the United States of America·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Cycle Regulation

Background:

  • Human cancers exhibit reduced dependency on growth factors (mitogens) and decreased sensitivity to growth-inhibiting signals.
  • These cancer hallmarks are often linked to compromised function of the retinoblastoma tumor suppressor protein (pRB).
  • pRB acts as a negative regulator of E2 transcription factors (E2Fs), which control cell cycle progression.

Purpose of the Study:

  • To review the critical role of E2F transcription factors in the development of human cancers.
  • To explore the potential of targeting E2F biology for novel anticancer therapeutic strategies.

Main Methods:

  • Review of existing scientific literature on pRB, E2F, cell cycle regulation, and cancer biology.
  • Analysis of the mechanisms by which E2F activation contributes to both proliferation and apoptosis in cancer.

Related Experiment Videos

Main Results:

  • Mutations compromising pRB function lead to dysregulated E2F activity.
  • Activated E2F drives unscheduled cell proliferation, a key feature of cancer.
  • E2F activation can also trigger programmed cell death (apoptosis) under specific conditions.

Conclusions:

  • The retinoblastoma protein (pRB) and E2F transcription factors are central players in cell cycle control and cancer development.
  • Understanding the intricate E2F pathway offers significant opportunities for developing targeted anticancer therapies.